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Themolecular events that contribute to the cellular uptake of
cell-penetrating peptides (CPP) are still a matter of intense
research.Here,we report on the identification and characteriza-
tion of a 22-amino acid CPP derived from the human milk pro-
tein, lactoferrin. The peptide exhibits a conformation-depen-
dent uptake efficiency that is correlatedwith efficient binding to
heparan sulfate and lipid-induced conformational changes. The
peptide contains a disulfide bridge formed by terminal cysteine
residues. At concentrations exceeding 10 M, this peptide
undergoes the same rapid entry into the cytoplasm that was
described previously for the arginine-rich CPPs nona-arginine
and Tat. Cytoplasmic entry strictly depends on the presence of
the disulfide bridge. To better understand this conformation
dependence,NMRspectroscopywasperformed for the free pep-
tide, and CD measurements were performed for free and lipid-
bound peptide. In solution, the peptides showed only slight dif-
ferences in secondary structure, with a predominantly
disordered structure both in the presence and absence of the
disulfide bridge. In contrast, in complex with large unilamellar
vesicles, the conformation of the oxidized and reduced forms of
the peptide clearly differed. Moreover, surface plasmon reso-
nance experiments showed that the oxidized form binds to
heparan sulfate with a considerably higher affinity than the
reduced form. Consistently, membrane binding and cellular
uptake of the peptidewere reducedwhen heparan sulfate chains
were removed.
Cell-penetrating peptides (CPPs)5 such as antennapedia-de-
rived penetratin (1) and theTat peptide (2) arewidely used tools
for the delivery of peptides, proteins, and oligonucleotides into
cells (3). Areas of application range from cell biology (4) to
biomedical research (5). Most CPPs used to date are of nonhu-
man origin, but the immunological relevance of these mole-
cules is particularly important to biomedical research. Espe-
cially when conjugated to proteins and nanoparticles, these
molecules may give rise to an adaptive immune response.
Therefore, CPPs such as the human calcitonin-derived peptide
(6) and peptides corresponding to signal sequences of human
proteins (7) are considered highly attractive import vehicles.
Human lactoferrin (hLF) is an 80-kDa iron-binding glyco-
protein of 703 amino acids (8). It constitutes about 15% of
human milk protein and also can be found in low concentra-
tions in blood plasma, tears, nasal fluids, saliva, pancreatic, gas-
trointestinal, and reproductive tissue secretions (9). With anti-
fungal, antimicrobial, and antiviral activities, the protein plays
an important role in the innate immune defense (10). In addi-
tion to iron depletion (11), the protein exerts its activity
through direct interaction with bacterial components (12).
The hLF N-terminal domain in particular carries potent
activity against pathogens (13). In the gastrointestinal tract this
domain canbe cleaved throughpepsin digestion resulting in the
release of an antimicrobial peptide called lactoferricin (14).
Human lactoferricin comprises 49 amino acids (20–68 of the
parent sequence) that form a loop stabilized by two disulfide
bonds. The peptide contains sections of hydrophobic and pos-
itively charged amino acids comparable with those found in
numerous peptides that display antimicrobial activity.
It has been demonstrated that antimicrobial peptides and
CPPs possess concordant functional characteristics. On one
hand, antimicrobial peptides are taken up intomammalian cells
(15), and on the other hand CPPs show antimicrobial activity
(16). Therefore, we considered whether a lactoferricin-derived
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peptide would also have the ability to act as a CPP by entering
into mammalian cells.
Here, we report the characterization of a new cell-penetrat-
ing peptide derived from the N-terminal domain of human
lactoferrin, which corresponds to amino acid residues 38–59
(19–40 of human lactoferricin). The peptide overlaps with the
lipopolysaccharide-binding region of lactoferricin (17). The
peptide, which shows a well defined structure-activity relation-
ship, enters cells efficiently. The uptake mechanism of the pep-
tide is concentration-dependent. Above a concentration
threshold, rapid delivery into the cytoplasm and nucleus is
observed, which has been described previously for the arginine-
rich CPPs nona-arginine and Tat-derived peptide (18–20).
Quite remarkably, the hLF-derived peptide (hereafter, hLFpep-
tide) contains only four arginine and two lysine residues.
Instead, an intramolecular disulfide bridge is required for effi-
cient uptake, demonstrating that having a high number of argi-
nine residues in the peptide sequence is not a prerequisite for
triggering the rapid import. Instead, for the hLF peptide effi-
cient import is strictly conformation-dependent.
A combination of surface plasmon resonance (SPR), NMR,
and circular dichroism experiments revealed conformation-de-
pendent interactions with heparan sulfate proteoglycans and
demonstrated that only the cyclic form of the peptide under-
goes a conformational transition when interacting with large
unilamellar vesicles. Heparinase treatment of cells reduced
membrane binding and uptake of the peptide, demonstrating
the relevance of heparan sulfate binding for the function of the
peptide as a CPP. By using a biotinylated analog of the peptide,
we validated the capacity of the peptide to mediate cellular
import of a protein cargo. These results illustrate that the hLF
peptide is a promising new candidate for a human CPP with a
structure-activity relationship that should stimulate further
research on the molecular principles that govern CPP interac-
tion with cell membranes.
EXPERIMENTAL PROCEDURES
Cells and Reagents—The human cervical carcinoma cell line
HeLa and the rat IEC-6 cell line were obtained from the Amer-
ican Type Culture Collection (Manassas, VA). 1,4-Dithio-
threitol was from Merck (Darmstadt, Germany). 3-(4,5-Di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT),
heparinases I–III, BSA, and glucose were obtained from Sigma.
Rottlerin was from Calbiochem. The Zenon mouse IgG1 Alexa
Fluor 647 labeling kit (specific for the Fc part of IgG1 antibod-
ies) was purchased from Invitrogen. The anti-heparan sulfate
(HS) VSV-tagged single chain antibody HS4C3 (21) and the
mouse anti-VSV (clone P5D4) antibody were a kind gift from
Dr. Toin van Kuppevelt (Dept. of Biochemistry, Radboud Uni-
versity Nijmegen Medical Centre, Nijmegen, The Nether-
lands). TCEP-HClwas obtained fromThermo Fisher Scientific.
The phospholipids DPC (dodecylphosphocholine), DMPC
(1,2-dimyristoyl-sn-glycero-3-phosphocholine), and DMPG
(1,2-dimyristoyl-sn-glycero-3-phosphoglycerol) used for vesi-
cle preparation were purchased from Avanti Polar Lipids (Ala-
baster, AL). Biotin-LC-hydrazide was from Pierce. HBS-P
buffer (10 mMHEPES, 150 mMNaCl, 3 mM EDTA, 0.005% sur-
factant P20, pH 7.4) was from Biacore AB (Uppsala, Sweden).
Peptide Synthesis—Unlabeled hLF peptide was supplied by
Thermo Fisher Scientific. The other peptides, purchased from
EMC Microcollections (Tu¨bingen, Germany), were labeled
fluorescently by N-terminal conjugation of 5(6)-carboxyfluo-
rescein. The purity of all peptides was determined by analytical
HPLC. The identity of the peptides was confirmed by matrix-
assisted laser desorption ionization time-of-flight (MALDI-
TOF) mass spectrometry. Peptides with a purity of less than
90% were purified by preparative HPLC.
Peptide Modification—For intramolecular disulfide bond
formation, peptides were oxidized by introducing pure oxygen
into the peptide solution followed by incubation at 37 °C for 2 h.
For reduction of the disulfide bond, 10 mM dithiothreitol was
added, and the peptide solution was then incubated for 2 h at
37 °C. Biotinylated hLF peptides (200 M) were bound to
streptavidin-Alexa Fluor 488 conjugates (50 M) (Invitrogen)
by incubation at 4 °C for 12 h in PBS. For analysis of cellular
uptake, the solution was diluted 1:10 with medium.
Flow Cytometry—HeLa cells were incubated with medium
containing peptides at the indicated concentrations for 45 min
at 37 °C. After incubation, cells were washed with medium,
detached by trypsinization for 5 min, suspended in PBS, and
measured immediately by flow cytometry (BD FACSCalibur
system, BD Biosciences). In each case, the fluorescence of
10,000 viable cells was acquired. Viable cells were gated based
on sideward and forward scatter.
Confocal Laser Scanning Microscopy—Confocal laser scan-
ning microscopy was performed on an inverted LSM510 laser
scanning microscope (Carl Zeiss, Go¨ttingen, Germany) using a
Plan-Apochromat 63/1.4 N.A. oil differential interference
contrast lens and a TCS SP5 confocal laser scanning micro-
scope (Leica Microsystems, Mannheim, Germany) equipped
with anHCXPlan-Apochromat 63/N.A. 1.2water immersion
lens. All peptide uptake measurements were performed with
living cells.
Incubation with Inhibitor—Cells were treated with rottlerin
(20 M) for 30 min at 37 °C. Then the medium was removed,
and medium containing peptide as well as the inhibitor was
added. After a 30-min incubation at 37 °C, cells were washed
twice with medium and analyzed by confocal laser scanning
microscopy or flow cytometry.
Immunofluorescence—HeLa cells were seeded at a density of
1.5 104/well in 8-well chambered coverglasses and cultivated
to 75% confluency, after which they were incubated with
medium containing 33 mIU/ml heparinases I, 8 mIU/ml hepa-
rinase II, and 5 mIU/ml heparinase III for 1 h at 37 °C or left
untreated. Then the cells were washed with ice-cold HBS/BSA/
glucose (10 mMHEPES, 135 mMNaCl, 5 mM KCl, 1 mMMgCl2,
1.8 mM CaCl2, pH 7.4, containing 0.1% (w/v) BSA and 5 mM
glucose) and incubated with the anti-HS antibody HS4C3 on
ice. After 1.5 h of incubation cells were washed with ice-cold
HBS/BSA/glucose. For visualization of bound antibodies, the
cells were incubated for 1 h with an anti-VSV antibody (P5D4)/
Zenon Alexa Fluor 647 conjugate on ice. The antibody staining
was analyzed by confocal laser scanning microscopy.
MTT Assay—HeLa cells were seeded in 96-well microtiter
plates (1.5 104/well) and cultivated overnight. The next day,
cells were incubated with peptides for 6 h or 24 h at 37 °C. Cell
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viability was measured using the colorimetric MTT dye. Cells
were incubatedwithMTTat a concentration of 1mg/ml for 4 h.
The formazan product was solubilized with SDS (10% (w/v) in
10 mM HCl). Cell viability was determined by measuring the
absorbance of each sample relative to a control not treated with
peptide at 570 nm using a microplate reader (SpectraMax 340,
Molecular Devices).
Preparation of CD Samples—The hLF peptide was dissolved
in phosphate buffer to a concentration of 0.1 mM. Reduction of
the disulfide bonds was obtained by adding a 30-fold molar
excess of TCEP-HCl with subsequent incubation for 2 h at
37 °C. Oxidation of the hLF peptide was obtained by purging
pure oxygen for 15 min and subsequent incubation for 2 h at
37 °C. The DMPC and DMPG lipids were dissolved in 50%
chloroform, 50% methanol (v/v) to prepare lipid stock solu-
tions.Aliquots of these stock solutionsweremixed to obtain the
DMPC:DMPG mixture (molar ratio 3:1). Subsequently, the
organic solvents were removed under a gentle stream of nitro-
gen followed by overnight vacuum evaporation to remove the
residual solvent from the respective DMPC or DMPC/DMPG
lipid films that had been formed in the vial. The lipid layerswere
dispersed by the addition of phosphate buffer, vigorous vortex-
ing (10 times, 1 min each), and homogenization by 10 freeze-
thaw cycles. Finally, large unilamellar vesicles were prepared by
means of 11 extrusion cycles using an Avanti Mini-Extruder
equippedwith a 100-nmpolycarbonate filter.Here, the temper-
ature was maintained above 40 °C by thermostatting the
extruder block at 50 °C.
For preparation of the final CD samples, aliquots of the oxi-
dized and reduced hLFpeptide solutionswere added to aliquots
of the respective buffers,micellar solutions, or lipid dispersions.
The final peptide concentration in all samples was 17.5 M, the
SDS and DPC concentration in the micellar solutions was 10
mM (peptide-to-detergent ratio 1:570), and the lipid concentra-
tion in the vesicle dispersions was 1.45 mM (peptide-to-lipid
ratio 1:80).
CD and UV Spectroscopy—CD spectra of the reduced and
oxidized hLF peptide in phosphate buffer, in membrane-mim-
icking environments such as 50% trifluoroethanol, 50% phos-
phate buffer solution or SDS and DPCmicellar solution, and in
DMPC and DMPG/DMPC vesicle dispersions were recorded
on a J-815 spectropolarimeter (Jasco, Gross-Umstadt, Ger-
many) equipped with 1mm-Suprasil quartz glass cells (Hellma,
Mu¨llheim, Germany). The samples were measured at a scan
rate of 10 nmmin1 and a 1-nm bandwidth in 0.1-nm inter-
vals between 260 and 185nmat 20 °C for the buffer andmicellar
solutions and at 30 °C for the vesicle suspensions, i.e. above the
phase transition temperature of the lipids contained in the ves-
icle suspensions. Three repeat scans were averaged for each
sample. CD spectra were smoothened by the adaptive smooth-
ing of Jasco Spectra Analysis software, and the secondary struc-
ture was analyzed by the CONTINLL program with the imple-
mented ridge regression algorithm (22, 23) provided on the
DICHROWEB server (24, 25). The quality of the fit between
experimental and back-calculated spectrum corresponding to
the derived secondary structure element fractions was assessed
from the normalized rootmean square deviationwith a value of
0.1 considered a good fit (25). For calculation of the mean
residue ellipticities used for the secondary structure estimation,
the resultswerenormalized toUVabsorbanceat280nmassuming
a molar extinction coefficient of 5625 litersmol1 cm1 for
the peptidewith oxidizedCys residues and 5500 litersmol1
cm1 for reduced Cys residues (26). The absorption spectrum
in the range of the aromatic bands due to tryptophan (and cys-
tine for the oxidized peptide) was recorded in the range of 240
to 340 nm using a quartz glass half-micro-cuvette with 1-cm
optical path length (Hellma). For correction of scattering, the
base line of a log absorbance against log wavelength from the
nonabsorbing region between 310 and 340 nm was extrapo-
lated toward lower wavelengths and subtracted from the mea-
sured spectrum to get the final spectrum (27).
NMR—All NMR samples were prepared using a Shigemi
NMR tube dissolving 0.83mg of hLF in 300l of 95:5 (v:v) H2O
buffer/D2O. Two-dimensional ROESY and NOESY experi-
ments employing aWATERGATE solvent suppression scheme
were performed at 10 or 20 °C on a Varian Inova 600-MHz
spectrometer equipped with a 5-mm triple resonance three-
axis gradient probe using a 200ms ROE or NOEmixing period.
The spectra were recorded as 2048 512 hypercomplex points
with 9009.1 8000Hz spectral widths for the F2 and F1 dimen-
sions, respectively. Spectra were transformed using the
nmrPipe processing package.
Surface Plasmon Resonance Binding Experiments—Surface
plasmon resonance experiments were conducted as described
previously (28). The reducing ends of 6-kDa HS were biotiny-
lated by preactivated biotin-LC-hydrazide (Pierce). The biotin-
ylation procedure was verified by streptavidin-peroxidase
labeling after blotting of the material onto a ZetaProbe mem-
brane. CM4 flow cell Biacore sensorchips were activated with
50 l of 0.2 M N-ethyl-N-(diethylaminopropyl)-carbodiimide
and 0.05 M N-hydroxysuccinimide before injection of 50 l of
streptavidin (0.2 mg/ml in 10 mM acetate buffer, pH 4.2). The
remaining activated groups were blocked with 50 l of 1 M
ethanolamine, pH 8.5. Typically, this procedure permitted the
coupling of 3.000–3.500 resonance units of streptavidin.
Subsequently, the biotinylated HS (10 g/ml) molecules were
immobilized by injection over a one-surface flow cell leading to
an immobilization level of50 resonance units. The flow cells
were then conditioned with several injections of 2 M NaCl.
Untreated one-flow cells served as the negative control. Bind-
ing assays were conducted with different concentrations of oxi-
dized and reduced hLF in HBS-P at 25 °C and a flow rate of 20
l/min. Regeneration of the sensorchip surfacewas achieved by
a 5-min pulse of 2 M NaCl in HBS-P buffer.
RESULTS
Cellular Uptake of the Human Lactoferrin-derived Peptide—
There are grave concerns about the potential immunogenicity
of peptides used in biomedicine. This is especially the case
when peptides are conjugated to larger molecular weight pro-
teins. Given recent observations that certain antimicrobial pep-
tidesmay act as cell-penetrating peptides, we selected a peptide
corresponding to amino acids 38–59 of human lactoferrin as a
potential candidate for a new CPP derived from a human pro-
tein. Previously, this peptide was shown to possess antimicro-
bial activity (29). The peptide comprises an exposed loop of the
Conformation-dependent Uptake of a Cell-penetrating Peptide
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lactoferrin protein that is terminally flanked by cysteine resi-
dues. These cysteine residues form a disulfide bridge, both in
the protein and in lactoferricin, a naturally occurring degrada-
tion product of lactoferrin. In our peptide, at the N-terminal
side of the first cysteine residue, a lysine residue of the lactof-
errin sequence was preserved. Similarly, a lysine and an argi-
nine residue from the lactoferrin sequence were included at the
C terminus of the second cysteine residue. Given the require-
ment for positive charge to promote cellular uptake, we rea-
soned that these three residues should promote the function of
the peptide as a CPP.
The peptide was synthesized as a peptide amide labeled with
carboxyfluorescein at itsN terminus. To apply stringent criteria
for classifying this peptide as a potential new CPP, uptake was
compared with the uptake of fluorescein-labeled analogs of the
well established CPPs penetratin and R9. HeLa cells were incu-
bated with these peptides at concentrations ranging from 5 to
20 M, and uptake was quantified in living cells by flow cytom-
etry. Trypsinization of cells (required to detach the cells from
the tissue culture plate prior to flow cytometry) was used to
remove peptides that weremerely adsorbed to the outer plasma
membrane.
All three peptides were taken up in a concentration-depend-
ent manner, and no saturation of uptake was observed (Fig. 1).
For penetratin, the cellular import was proportional to the con-
centration of peptide present in the medium. R9 uptake
increased strongly at 20 M, which very likely reflects the effi-
cient cytoplasmic uptake via localized areas of the plasmamem-
brane that we have called nucleation zones (NZ) (18). Uptake of
the hLF peptide also showed clear concentration dependence.
The relative increase in uptake from 10 to 20 M was notably
stronger than from 5 to 10 M.
Intracellular Distribution of the hLF Peptide—Given our
recent observation of a rapid cytoplasmic delivery of certain
CPPs at higher concentrations, we were particularly interested
in investigating the concentration dependence of the intracel-
lular distribution of the hLF peptide. The intracellular localiza-
tion of the peptide in living cells was investigated by confocal
microscopy. For concentrations up to 10 M the peptide was
localized predominantly in vesicles (Fig. 2A). In contrast, at a
concentration of 20 M, next to a vesicular staining, nearly all
cells showed a homogeneous cytoplasmic and nuclear peptide
distribution. This concentration dependence of the intracellu-
lar distribution very much resembled our former observations
for the R9 and Tat peptides (18) of a cytoplasmic entry via NZ.
In order to further establish that entry of the hLF peptide
occurred via the same process, we followed the uptake by time
lapse confocal fluorescence microscopy. This experiment con-
firmed the induction of NZ as the basis for rapid entry (not
shown). We had shown previously that for arginine-rich pep-
tides this rapid entry is associated neitherwithmembrane dam-
age nor with cytotoxicity. To exclude also for the hLF peptide
the suggestion that cytoplasmic delivery results in cell death,
HeLa cells were incubated with peptide for 6 and 24 h, and cell
viability was assessed by theMTT assay. After 6 h of incubation
the cells were viable at peptide concentrations up to 40 M,
whereas viability was reduced by 25% for cells incubated for
24 h at a peptide concentration of 10 M.
Structure-Activity Relationship of the hLF Peptide for Effi-
cient Uptake—After testing the uptake properties and intracel-
lular distribution, we were interested in defining the structure-
activity relationship of the hLF peptide for efficient cellular
uptake.With 22 amino acids, the hLF peptide is a CPP of inter-
mediate length. Four of the seven cationic amino acids and the
aromatic amino acids are localized in the sequence nested
between the cysteine residues. Positively charged and aromatic
residues are typically associated with CPP activity. In the full-
length protein, the cysteine residues formadisulfide bridge that
constrains the domain into a loop conformation (30).
First, we wondered whether a shorter peptide would also
show efficient import (Table 1). Removal of the three C-termi-
nal residues following the cysteine residue was tolerated (Fig.
3A). In contrast, as soon as a cysteine residue was omitted,
FIGURE1.Concentrationdependenceofuptake.HeLa cellswere incubated
with increasing concentrations of the indicated peptides for 45 min. After-
ward the cells were washed with cold PBS and harvested with trypsin/EDTA.
Uptake into cells was analyzed by flow cytometry. Left, flow cytometry histo-
grams of cells incubated with 20 M solutions of penetratin (top), nona-argi-
nine (R9) (middle), and hLF (bottom). The arrow in the bottom panel indicates
the fraction of cells showing efficient peptide uptake. Right, median cellular
fluorescence. The results of two independent experiments were normalized
to median fluorescence for 20 M hLF. The error bars correspond to the aver-
age deviation of two independent experiments. Pen, penetratin.
FIGURE 2. Concentration-dependent phenotypes for the cellular uptake
of thehLFpeptideand toxicity.A, HeLa cellswere incubated for 30minwith
different concentrations of the peptide. After two washing steps, the cellular
peptide uptake was analyzed by confocal laser scanning microscopy. The
scale bar indicates 20 m. B, HeLa cells were incubated with increasing con-
centrations of the hLF peptide for 6 h (squares) or 24 h (circles), and subse-
quently cell viability was determined using the MTT assay.
Conformation-dependent Uptake of a Cell-penetrating Peptide
36102 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284•NUMBER 52•DECEMBER 25, 2009
 at INSERM
, on January 19, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
import efficiency was reduced dramatically. This result sug-
gested a structural requirement for the formation of the disul-
fide bridge in order to obtain efficient import.We therefore also
tested a peptide in which the cysteine residues were exchanged
for serine residues. Again, import of the resulting analog was
reduced drastically. This finding further demonstrates that effi-
cient uptake can be attributed to the capacity of the cysteines to
form a disulfide bridge. Formation of the disulfide bridge was
confirmed analytically by mass spectrometry (see below). We
validated the result by confocal microscopy, comparing the
uptake of hLF and theCys3 Ser hLFmutant (M2) (Fig. 3B). For
the mutant peptide the intracellular distribution was strictly
vesicular. Also, at higher concentrations the cytoplasmic
import could not be observed, demonstrating that this import
was a function of the disulfide bridge.
Comparison with an hLF Analog of a Different Species—To
test whether only the number of positively charged side chains
was essential for efficient uptake or whether additional
sequence-specific elements were also involved, the uptake of
hLF was compared with a rat-derived lactoferrin peptide con-
taining six positively charged amino acids versus seven for the
hLF peptide. Especially for the sequence nested within the
disulfide bridge, the position of positively charged residues dif-
fered. Neither for HeLa cells nor for rat IEC-6 cells was an
efficient cytoplasmic uptake observed (Fig. 4), indicating the
importance of the specific sequence of hLF and that efficient
uptake is not related to the species from which the peptide and
target cells originated.
Structural Analyses—The cellular uptake experiments pro-
vided strong functional evidence for the requirement of cycli-
zation for the efficient cellular import of the hLF peptide.
Therefore, we next addressed explicitly the structure of the
peptide and how this structure depends on the presence of the
disulfide bridge. The hLF peptide comprises the loop and one
disulfide bridge of human lactoferricin, which at pH 4 forms a
nascent helix (31). Formation of the disulfide bridge upon oxi-
dation was confirmed by mass spectrometry (Fig. 5, A and B).
First, we addressed conformational differences in the
reduced and oxidized cyclic form of the peptide using NMR.
The spectra showed relatively broad and ill-defined peaks and
only limited ROE cross-peak patterns. In particular, no amide-
amide ROE or NOE cross-peaks indicative of helix formation
were observed, and amide-H cross-peaks in the fingerprint
region did not identify significantly downfield-shifted H reso-
nances indicative of extended conformation and expected for
theN-terminal residues of the peptide (Fig. 5C). The absence or
presence of the disulfide bridge did not result in major changes
in the appearance of the NMR spectra. Lowering the tempera-
ture to 10 °C also did not result in a substantial improvement of
the spectrum. In contrast to the NOE spectra recorded previ-
ously for the longer lactoferricin peptide (13), the ROESY spec-
tra recorded on the hLF discriminated cross-peaks resulting
from the ROE from those originating from chemical exchange
on the basis of their sign. Interestingly, clear exchange cross-
peaks were observed in the aromatic/amide region as well as in
the aliphatic region of the spectrum (Fig. 5,D andE). Dissolving
the peptide in the solvent mixture H2O:CD3OD:CDCl3 (1:4:4
(w/w/w)) as done previously (31) did not radically change the
spectral appearance, although an increase in spectral dispersion
was observed, and weak, upfield-shifted H resonances as well
as downfield-shifted methyl resonances suggested the forma-
tion of an extended structure (not shown). However, relatively
broad lines were again observed in conjunction with a lack of
cross-peaks in the fingerprint and amide regions. It is notewor-
FIGURE 3. Structure-activity relationship of hLF. A, HeLa cells were incu-
bated with increasing concentrations of the indicated peptides for 30 min.
Afterward the cells were washed and harvested with trypsin/EDTA. Uptake
into cells was quantitated by flow cytometry. B, HeLa cells were incubated
with increasing concentrations of the indicated peptides for 30min, washed,
and analyzed by confocal laser scanning microscopy. The scale bars indicate
20 m. a.u., arbitrary units.
TABLE 1
Primary structures of the peptides used in this study
All peptides were synthesized as C-terminal peptide amides (-CONH2), rLF, rat
lactoferrin; Fluo, 5(6)-carboxyfluorescein; Ahx, aminohexanoic acid.
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thy that under all conditions, the single, easily identifiableTrp42
(Trp5 peptide) side chain N1 proton shows as much as four
different resonances of varying intensities. Overall, the NMR
data suggest a potentially oligomeric, partially folded state, sub-
ject to conformational exchange.
Having failed to observe an oxidation-dependent conforma-
tional difference in an aqueous buffer, we next employed CD
spectroscopy to obtain information about the secondary struc-
ture in membrane-mimicking environments and in buffers
containing micelles or vesicles. Consistent with the NMR anal-
ysis, in aqueous buffer, reduction of the disulfide bridge by
incubation with dithiothreitol had no effect on the shape of the
CD spectrum in a temperature range of 5 to 20 °C (not shown).
The CD spectra could not be described by a linear combination
of CD spectra for classical secondary structure elements, i.e.
-helix, -sheet, and random coil. However, the spectrum was
also distinct from that expected for purely random coil. The
addition of 50% trifluoroethanol led to the formation of an
-helix in the reduced and oxidized states of the peptide.
In contrast, both forms showed different spectra in solutions
containing detergent or lipid. SDS increased the -sheet con-
FIGURE 4. Comparison of the uptake of human (hLF) and rat-derived LF
(rLF) peptides in HeLa (A) and rat IEC-6 (B) cells. Cells were incubated with
5 and 20 M human or rat lactoferrin for 60 min at 37 °C in RPMI supple-
mented with 10% fetal calf serum. Cells were washed twice and imaged
immediately using confocal microscopy. The scale bars indicate 20 m.
FIGURE 5. Structural analyses at micellar membranes. A and B, electron
spraymass spectrometry of the reduced (A) and oxidized (B) forms of the hLF
peptide. The signals of the differently charged species of the molecules cor-
respond to an m/z difference of 2 Da of the reduced form of the peptide.
C, NOESY spectrum of 1 mM hLF in H2O solution. D and E, upfield (D) and
aliphatic (E) regions of the ROESY spectrum of hLF in H2O solution. Cross-
peaks with negative intensity (corresponding to ROE peaks) are shown as
single contours, whereas cross-peaks with positive signs (corresponding to
the diagonal and exchange peaks) are shown with multiple, exponentially
spaced contours. F and G, CD spectroscopy in an aqueous phosphate buffer
(F) and phosphate buffer containing DMPC/DMPG 3:1 vesicles (G). H and I,
data analysis via the CONTINLL algorithm of the reduced peptide (H) and the
oxidized hLF peptide (I). Especially at the surface of DMPC/DMPG 3:1 vesicles
(indicated by arrows), -strand formation was induced for the oxidized form
of the peptide.
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tent in the reduced form only, whereas DPC increased the con-
tent in the reduced and in the oxidized form. In contrast, for
DMPC and DMPC/DMPG, the -sheet content increased only
for the oxidized form, with DMPC/DMPG inducing the most
pronounced changes (Fig. 5, F--I). The latter results demon-
strate that oxidation affects the capacity of the peptide to
undergo conformational changes.
Binding of the hLF Peptide and hLF Cys 3 Ser to Heparan
Sulfate Proteoglycans—Heparan sulfate proteoglycans report-
edly contribute to the uptake of several CPPs (32, 33). There-
fore, these sugars may also contribute to the dependence of
uptake on the presence of the disulfide bridge. We addressed
the binding of the oxidized and reduced hLF peptide to HS
chains with an SPR-based binding assay, a physiologically rele-
vant system in which a low amount of HS is coupled through its
reducing end to a sensorchip, thus representing HS proteogly-
can presentation at the cell surface. Injection of reduced hLF
over this surface, in the 250 to 3000 nM range, gave binding
curves that reached a plateau at 25–75 resonance units,
whereas the oxidized form of the peptide gave binding curves
reaching a plateau at 48–156 resonance units (Fig. 6). From the
binding curves of the oxidized peptide, a KD value of 2 M was
obtained. In a similar set of experiments in which binding of
fluorescein-labeled hLF was compared with binding of the flu-
orescein-labeled Cys 3 Ser mutant, a KD value of 10 M was
obtained for the wild-type hLF, whereas no binding could be
detected for themutant peptide (not shown). These results val-
idate the specificity of binding of the hLF peptide for HS. The
residual binding obtained for the reducedpeptidemay be due to
incomplete reduction.
HS Proteoglycan Dependence and Rottlerin Sensitivity of the
Uptake—Having observed a strong conformational depen-
dence of the binding of the hLF peptide to HS using biochemi-
cal assays, we next addressed the relevance of this interaction
for the binding to cells. Removal of HS chains after a 1-h treat-
ment with heparinases I–III nearly abolished the binding of the
hLF peptide to the cell surface and reduced the number and
intensity of vesicles (Fig. 7A).
Furthermore, we tested the effect of rottlerin on the cytoplas-
mic uptake of the oxidized hLF peptide. Rottlerinwas described
originally as a PKC inhibitor with its strongest activity toward
the protein kinase C- isoform (35). However, the specificity
was questioned later (36). Previously, we showed that this drug
acts as an effective inhibitor of cellular peptide uptake via nucle-
ation zones (18). Cells were preincubated with rottlerin, and
peptide uptake was analyzed by flow cytometry and fluores-
cence microscopy (Fig. 7, B and C). At low peptide concentra-
tions, at which only vesicular uptake occurred, rottlerin
reduced uptake only weakly. At peptide concentrations at
which uptake via NZ occurred, peptide uptake was inhibited by
up to 50%. Confocalmicroscopy confirmed that rottlerin only
inhibits efficient cytoplasmic peptide uptake. The concen-
tration-dependent increase in cell-associated fluorescence
observed in the presence of rottlerin (Fig. 7B) may therefore be
attributed to vesicular peptide uptake, which is not affected by
rottlerin.
hLF-mediated Import of ProteinCargos—The ability tomedi-
ate the cellular uptake of a diverse set of cargos is an important
characteristic for a CPP, making it valuable for applications in
biological and biomedical research.
As such, the fluorophore could
already be considered a cargo, as it
may affect the cellular trafficking of
a CPP (37). Therefore, our data sug-
gest that lactoferrin is well suited for
the efficient cellular import of small
molecules that otherwise cross the
plasma membrane only poorly.
In addition, we tested whether
the hLF peptide was able to mediate
the import of a large molecular
weight protein cargo. For these
complexes, potential immunoge-
nicity of the CPP is an important
concern. Therefore, using a human
protein-derived peptide is of partic-
ular importance. To this end, a bio-
tinylated hLF was synthesized and
coupled to Alexa 488-labeled
streptavidin in a molar ratio of 4:1
(peptide:streptavidin). Import of
these conjugates intoHeLa cells was
FIGURE 6. Affinity measurements of oxidized (A) and reduced (B) hLF for
HS-coated surfaces using SPR. RU, resonance units.
FIGURE7.Cytoplasmic importofhLF isHSproteoglycan-dependentandnegativelyaffectedby rottlerin.
A, HeLa cells were treated for 1 h with heparinases I, II, and III (33, 8, and 5 mIU/ml, respectively) or remained
untreated. Subsequently, the cells were washed and incubated with different concentrations of the hLF pep-
tide. Images were taken after 30 min of peptide incubation. Removal of HS chains from the cell surface was
confirmed by immunofluorescence staining of treated and untreated cells. B and C, HeLa cells were treated
with 20 M rottlerin for 30 min or remained untreated. After one washing step the cells were incubated with
different concentrations of hLF in the presence (white bars) or absence of rottlerin (black bars) (B). After 30min
of incubation the cells were analyzed by flow cytometry or confocal laser scanning microscopy (C). The scale
bars indicate 20 m. a.u., arbitrary units.
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visualized by confocal fluorescence microscopy (Fig. 8).
Streptavidin-Alexa 488 was internalized into vesicular com-
partments in accordance with observations for high molecular
weight complexes of other CPPs (20). This uptake occurred
only when the protein was conjugated to biotinylated hLF pep-
tide. Neither the protein alone nor the protein in the presence
of non-biotinylated hLF peptide was taken up.
DISCUSSION
The results shown in this article present a new cell-penetrat-
ing peptide corresponding to amino acids 38–59 of human
lactoferrin (amino acids 19–40 of human lactoferricin). With
22 amino acids, the hLF peptide is aCPP of intermediate length.
Nevertheless, repeated batches of the peptide obtained by sol-
id-phase peptide synthesis following standard procedures
showed the typical purities of the N-terminally labeled peptide
to be about 80%.
In contrast to shorter ones, oligoarginine peptides of more
than eight amino acids in length enter cells more efficiently and
show a concentration-dependent uptake mechanism into the
cytoplasm (19). Even though the hLF peptide contains less argi-
nine residues than the Tat peptide or R9, a concentration-de-
pendent uptake mechanism was also observed. At concentra-
tions higher than 10 M, the peptide rapidly enters the
cytoplasm. The sensitivity of this uptake to rottlerin treatment
of cells suggests that thismechanism is the same as observed for
R9 and the Tat peptide. Thus far, the rottlerin-sensitive uptake
mechanism had been observed only for arginine-rich CPPs.
Our observations on the conformation-dependent uptake of
the hLF peptide suggest that the particular structure of this
peptide may functionally replace the high arginine content for
this mechanism of cell entry.
The sequence nestedwithin the two cysteine residues is rem-
iniscent of cationic amphipathicCPPs such as penetratin.How-
ever, removal of the disulfide bridge, either by reduction of
cysteine residues (not shown) or their replacement by serine
residues, strongly reduced the capacity of the peptide to enter
cells. To our knowledge, this is the first report of a cell-pene-
trating peptide that requires a cyclic structure for its activity.
However, numerous antimicrobial peptides have been investi-
gated to this aim, such as gramicidin S (38), protegrin-1 (39),
RTD-1 (40), ranatuerin-1 (41), bactenecin (42), and tachyple-
sin-1 (43–45), althoughwith differing results. In the latter case,
aggregation was found to be the deactivating factor, which
could be prevented by proper cyclization.
Dependence on a disulfide bridge for efficient import is not
predicted by our current knowledge ofCPPs.Aprediction iden-
tified the central QWQRNMRKVR motif as essential for CPP
activity (46). The terminal residues in the cysteine-containing
wild-type peptide as well as the serine-containing mutant ana-
log are not predicted to influence the uptake significantly.6 Fur-
thermore, comparisonwith the corresponding disulfide bridge-
containing rat-derived lactoferrin peptide identified the hLF
peptide as a far superior CPP, despite a similar number of pos-
itively charged amino acids. These considerations indicate that
for the hLF peptide, a simple examination of the primary struc-
ture fails to predict the structural determinants required for
efficient cell entry of the peptide. The hLF also demonstrated a
more efficient uptake comparedwith rat lactoferrin in IEC-6 rat
cells, indicating the absence of an evolutionary constraint on
the internalization efficiency.
In the crystal structure of human lactoferrin (47), the resi-
dues corresponding to hLF are part of an -- motif that is
stabilized by the formation of a disulfide bridge between Cys39
and Cys56 (positions 2 and 19 in the peptide) and hydrophobic
interactions that involve Trp42 and Val54 (positions 5 and 17 in
the peptide) and Met46 and Pro52 (positions 9 and 15 in the
peptide). For the human lactoferricin peptide, NMR data indi-
cate that the amino acid residues corresponding to the hLF
peptide adopt a “nascent” helical structure in aqueous solutions
and a conformation resembling the crystal structure in mem-
brane-mimicking solvent. Our data clearly show the necessity
of the presence of the Cys39-Cys56 (positions 2 and 19 in the
peptide) disulfide bridge for efficient import. However, in solu-
tion, neitherCDnorNMRspectrawere significantly affected by
disulfide formation. Whereas the CD data indicate a non-ran-
dom coil conformation of hLF, the NMR data also point to
conformational exchange. It is tempting to speculate that Trp42
(position 5 in the peptide) is a crucial factor affecting the NMR
spectra because of its essential structural role and the putative
large changes in shielding effects that it exerts. Other dynamic
effects, such as dimer formation, could similarly affect theNMR
spectra; such a phenomenon was postulated for the longer
human lactoferricin peptide in aqueous solvent (31).
Therefore, CD spectra were also recorded in the presence of
phospholipid micelles in order to gain further insights into the
structural impact of lipid surfaces on the peptide. Here, the
oxidized peptide showed a clear preference for-strand forma-
tion, whereas the reduced peptide presented no defined sec-
ondary structure. Interestingly, the differences in secondary
structure formation between the oxidized and reduced hLF
peptide weremost pronounced in the presence of DMPC/DMPG
vesicles; this ensures strong electrostatic attraction of the peptide
and is also a good mimic of the cellular membrane environment.
Additionally, the interaction with heparan sulfate chains was
investigated by surface plasmon resonance and in cellular assays.
SPRexperiments showed that the interactionwithHS is enhanced
significantly upon oxidation of the peptide.
6 M. Ha¨llbrink, personal communication.
FIGURE 8. Biotinylated hLF peptide efficiently transports streptavidin-
Alexa 488 into cells. HeLa cells were incubated for 30 min with biotinylated
hLF-streptavidin-Alexa 488 complex (5 M). After two washing steps, cellular
uptake was analyzed by confocal laser scanning microscopy. Coincubations
of streptavidin with PBS (left) and non-biotinylated hLF peptide (middle)
served as controls. The scale bar indicates 20 m.
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Cellular assays show the physiological relevance of the differ-
ent HS-peptide interactions. In cell experiments we made an
interesting additional observation concerning the involvement
of HS proteoglycans in NZ-dependent cytoplasmic uptake.
Consistent with our previous results, heparinase treatment
over a period of 6 h abolished the rapid cytoplasmic uptake of
hLF (not shown). In contrast, short term treatment over only
1 h had no significant effect on NZ-dependent import. How-
ever, membrane binding of hLF at lower peptide concentra-
tions was strongly reduced. We therefore concluded that the
previously observed effect of long term heparinase treatment
on NZ-dependent uptake was due to perturbations of mem-
brane protein organization ormolecular events involved in this
cytoplasmic uptake.
Given that the cell uptake experiments did not show any
concentration-dependent saturation, the lactoferrin-derived
CPP exhibited one of the most prominent characteristics for
the uptake of CPPs. In the full-length lactoferrin protein, cellu-
lar uptake has been described for various cellular systems.
Although it has been observed that the polycationic nature of
the N terminus by itself confers an interaction with sugars on
the cell surface, cellular uptake and the biological effects of
lactoferrin have been attributed to its binding to one of the
several receptors identified for this protein (48). In contrast to
our peptide, binding to these receptors was therefore saturable.
Quite remarkably, regarding binding to the lymphocyte lacto-
ferrin receptor and the platelet lactoferrin receptor, evidence
has been obtained for the involvement of the loop domain cor-
responding to the lactoferrin-derived CPP (49, 50). Competi-
tion experiments with our peptide for the binding of lactoferrin
may thus help to better define ligand binding domains for other
types of lactoferrin receptors.
In summary, the results show that the hLF peptide is a new
CPP with highly interesting structural and functional charac-
teristics. With respect to the mechanism of import, we expect
that further analyses of the structure-activity relationship will
yield new insights into the molecular determinants of the cell
surface that mediate the molecular interaction and induce the
efficient cellular import via nucleation zones. Furthermore, it
will be interesting to compare analogous peptides derived from
lactoferrin of different species. In the past, the antimicrobial
characteristics of bovine lactoferrin-derived peptides have been
compared in detail with those of their human counterparts (13).
Because of its human origin, the hLF peptide is expected to be
non-immunogenic. For this reason, thismolecule is a candidate
vector for biomedical applications, especially for the import of
high molecular weight complexes.
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